Novartis AG (NVS) AI Stock Analysis

Novartis AG is a Swiss-based healthcare company that researches, develops, manufactures, and markets healthcare products globally. Operating through two main segments, Innovative Medicines and Sandoz, the company provides prescription medicines across therapeutic fields including cardiovascular health, ophthalmology, neuroscience, immunology, hematology, and solid tumors. The Innovative Medicines segment advances novel therapies, while Sandoz focuses on finished dosage forms of small molecule pharmaceuticals, biotechnology-based products, biosimilars, and contract manufacturing services. Established in 1996 and based in Basel, Switzerland, Novartis also pursues strategic collaborations, such as its partnership with Alnylam Pharmaceuticals to develop inclisiran for lowering LDL cholesterol.

Between FY2021 and FY2025, Novartis expanded revenue from $43.97B to $54.81B, reflecting a 5-year revenue CAGR of 1.9%. Operating margin improved from 22.9% in FY2021 to 31.2% in FY2025, while gross margin climbed from 73.3% to 75.0%. Net income stood at $14.06B in FY2025 with diluted EPS of $8.98, supported by free cash flow of $17.69B and R&D spending of $10.74B. Over the trailing twelve months ended June 30, 2026, revenue totaled $56.69B with an operating margin of 34.6% and profit margin of 22.5%. In the latest quarter, revenue grew 0.8% year-over-year while quarterly earnings fell 17.0%.

As of June 30, 2026, Novartis held $7.69B in cash and short-term investments against total debt of $49.01B, resulting in net debt of $41.32B. Shareholders' equity was $41.54B, with a debt-to-equity ratio of 1.18 and a current ratio of 0.86. In FY2025, operating cash flow reached $19.24B. The company directed capital toward $1.56B in capital expenditures, $7.86B in dividends paid, and $9.26B in share buybacks, contributing to a 15.0% reduction in share count over 5 years.

Novartis has a market capitalization of $286.29B and an enterprise value of $313.60B. The stock trades at a trailing P/E of 22.8x and a forward P/E of 14.7x, both below the median of its US-listed Healthcare peers (24.6x trailing and 17.3x forward). Its EV/EBITDA multiple of 14.0x is above the peer median of 12.0x, while its price-to-sales ratio is 5.0x compared to 4.1x for peers. Over the past year, NVS returned 18.7% versus 16.8% for the S&P 500, and over five years returned 118.0% compared to 83.0% for the S&P 500.

Novartis pays an annual dividend with a forward rate of $4.74 per share, translating to a dividend yield of 3.15%. Its payout ratio is 57.2%, and the company has paid dividends for 30 consecutive years. The annualized 5-year dividend growth rate is 5.6%, with the last ex-dividend date on March 11, 2026.

Wall Street coverage includes 2 Strong Buy, 3 Buy, 6 Hold, 0 Sell, and 1 Strong Sell ratings. The mean price target is $154.65, representing a 2.7% premium over the last close of $150.62. For the fiscal year ending December 31, 2026, analysts estimate EPS of $8.83 on revenue of $57.66B. For FY2027, consensus estimates project EPS of $9.80 on revenue of $61.34B. Novartis beat EPS estimates in 2 of the last 4 quarters, with the next earnings release scheduled for October 27, 2026.

This page is an AI-written research summary of Novartis AG (NVS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NVS income statement, NVS balance sheet, NVS key metrics, NVS analyst forecast, NVS chart. See the NVS stock overview for the latest quote and news.